A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine

David Porter, Fiona Thompson, Tamara Berthoud, Claire Hutchings, Laura Andrews, Sumi Biswas, Ian Poulton, Eric Prieur, Simon Correa, Rosalind Rowland, Trudie Lang, Jack Williams, Sarah Gilbert, Robert Sinden, Stephen Todryk, Adrian Hill

Research output: Contribution to journalArticlepeer-review

45 Citations (Scopus)


We examined the safety, immunogenicity and efficacy of a prime-boost vaccination regime involving two poxvirus malaria subunit vaccines, FP9-PP and MVA-PP, expressing the same polyprotein consisting of six pre-erythrocytic antigens from Plasmodium falciparum. Following safety assessment of single doses, 15 volunteers received a heterologous prime-boost vaccination regime and underwent malaria sporozoite challenge. The vaccines were safe but interferon-γ ELISPOT responses were low compared to other poxvirus vectors, despite targeting multiple antigens. There was no vaccine efficacy as measured by delay in time to parasitaemia. A number of possible explanations are discussed, including the very large insert size of the polyprotein transgene.
Original languageEnglish
Pages (from-to)7514-7522
Issue number43
Publication statusPublished - 6 Oct 2011


Dive into the research topics of 'A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine'. Together they form a unique fingerprint.

Cite this